File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Targeted inhibition of COX-2 expression by RNA interference suppresses tumor growth and potentiates chemosensitivity to cisplatin in human gastric cancer cells.

TitleTargeted inhibition of COX-2 expression by RNA interference suppresses tumor growth and potentiates chemosensitivity to cisplatin in human gastric cancer cells.
Authors
KeywordsCOX-2
Gastric cancer
RNAi
Issue Date2007
PublisherDemetrios A Spandidos Ed & Pub. The Journal's web site is located at http://147.52.72.117/OR/or.htm
Citation
Oncology Reports, 2007, v. 18 n. 6, p. 1557-1562 How to Cite?
AbstractAlthough selective cyclooxygenase-2 (COX-2) inhibitors suppress cell proliferation in gastric cancer, it remains debatable whether their effect is mediated through COX-2 dependent or independent pathways. We investigated the effects of the targeted inhibition of COX-2 expression by small interfering RNA (siRNA) in human gastric cancer cells and compared it to the effects of treatment with a specific COX-2 inhibitor. COX-2 mRNA and proteins were significantly reduced by up to 80% on day 2 after COX-2 siRNA transfection to the gastric cancer cell line MKN45. Concentrations of prostaglandins E2 (PGE2) in the condition medium were also reduced to 30% after siRNA transfection. Transfection of COX-2 siRNA exhibited a more potent anti-proliferative effect on MKN45 cells than treatment with high-dose (100 microM) NS398. COX-2 siRNA also significantly reduced tumor growth in nude mice. While COX-2 siRNA transfection alone had no obvious pro-apoptotic effects, unlike low-dose (10 microM) NS398 it enhanced the apoptotic reaction of MKN45 cells to cisplatin therapy. In conclusion, our results demonstrate for the first time that COX-2 siRNA inhibits cell growth and enhances the chemosensitivity of gastric cancer cells. RNA interference may be a promising alternative to specific COX-2 inhibitors in the prevention and treatment of gastric cancer.
Persistent Identifierhttp://hdl.handle.net/10722/163138
ISSN
2023 Impact Factor: 3.8
2023 SCImago Journal Rankings: 0.864
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChan, MWen_US
dc.contributor.authorWong, CYen_US
dc.contributor.authorCheng, ASen_US
dc.contributor.authorChan, VYen_US
dc.contributor.authorChan, KKen_US
dc.contributor.authorTo, KFen_US
dc.contributor.authorChan, FKen_US
dc.contributor.authorSung, JJen_US
dc.contributor.authorLeung, WKen_US
dc.date.accessioned2012-09-05T05:28:04Z-
dc.date.available2012-09-05T05:28:04Z-
dc.date.issued2007en_US
dc.identifier.citationOncology Reports, 2007, v. 18 n. 6, p. 1557-1562en_US
dc.identifier.issn1021-335Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/163138-
dc.description.abstractAlthough selective cyclooxygenase-2 (COX-2) inhibitors suppress cell proliferation in gastric cancer, it remains debatable whether their effect is mediated through COX-2 dependent or independent pathways. We investigated the effects of the targeted inhibition of COX-2 expression by small interfering RNA (siRNA) in human gastric cancer cells and compared it to the effects of treatment with a specific COX-2 inhibitor. COX-2 mRNA and proteins were significantly reduced by up to 80% on day 2 after COX-2 siRNA transfection to the gastric cancer cell line MKN45. Concentrations of prostaglandins E2 (PGE2) in the condition medium were also reduced to 30% after siRNA transfection. Transfection of COX-2 siRNA exhibited a more potent anti-proliferative effect on MKN45 cells than treatment with high-dose (100 microM) NS398. COX-2 siRNA also significantly reduced tumor growth in nude mice. While COX-2 siRNA transfection alone had no obvious pro-apoptotic effects, unlike low-dose (10 microM) NS398 it enhanced the apoptotic reaction of MKN45 cells to cisplatin therapy. In conclusion, our results demonstrate for the first time that COX-2 siRNA inhibits cell growth and enhances the chemosensitivity of gastric cancer cells. RNA interference may be a promising alternative to specific COX-2 inhibitors in the prevention and treatment of gastric cancer.en_US
dc.languageengen_US
dc.publisherDemetrios A Spandidos Ed & Pub. The Journal's web site is located at http://147.52.72.117/OR/or.htmen_US
dc.relation.ispartofOncology reportsen_US
dc.subjectCOX-2-
dc.subjectGastric cancer-
dc.subjectRNAi-
dc.subject.meshAntineoplastic Agents - Therapeutic Useen_US
dc.subject.meshCell Division - Drug Effectsen_US
dc.subject.meshCell Line, Tumoren_US
dc.subject.meshCisplatin - Therapeutic Useen_US
dc.subject.meshCyclooxygenase 2 - Geneticsen_US
dc.subject.meshGene Expression Regulation, Enzymologic - Drug Effectsen_US
dc.subject.meshGene Expression Regulation, Neoplastic - Drug Effectsen_US
dc.subject.meshHumansen_US
dc.subject.meshPlasmidsen_US
dc.subject.meshRna Interferenceen_US
dc.subject.meshRna, Messenger - Geneticsen_US
dc.subject.meshRna, Small Interfering - Geneticsen_US
dc.subject.meshStomach Neoplasms - Drug Therapy - Pathologyen_US
dc.titleTargeted inhibition of COX-2 expression by RNA interference suppresses tumor growth and potentiates chemosensitivity to cisplatin in human gastric cancer cells.en_US
dc.typeArticleen_US
dc.identifier.emailLeung, WK:waikleung@hku.hken_US
dc.identifier.authorityLeung, WK=rp01479en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid17982644-
dc.identifier.scopuseid_2-s2.0-38449112343en_US
dc.identifier.volume18en_US
dc.identifier.issue6en_US
dc.identifier.spage1557en_US
dc.identifier.epage1562en_US
dc.identifier.isiWOS:000251353300029-
dc.publisher.placeGreeceen_US
dc.identifier.scopusauthoridChan, MW=7402597788en_US
dc.identifier.scopusauthoridWong, CY=25947838400en_US
dc.identifier.scopusauthoridCheng, AS=7402075036en_US
dc.identifier.scopusauthoridChan, VY=8599737600en_US
dc.identifier.scopusauthoridChan, KK=8599737700en_US
dc.identifier.scopusauthoridTo, KF=7101911940en_US
dc.identifier.scopusauthoridChan, FK=7202586434en_US
dc.identifier.scopusauthoridSung, JJ=24473715000en_US
dc.identifier.scopusauthoridLeung, WK=7201504523en_US
dc.identifier.issnl1021-335X-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats